Last reviewed · How we verify
NCT06926179
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
trial testing neoadjuvant immunotherapy in Lung Cancer (NSCLC) in 500 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 December 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2028 |
| Sites | 4 locations across China |
Drugs / interventions tested
- neoadjuvant immunotherapy — full drug profile →
Conditions studied
- Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →
- Neoadjuvant Immunotherapy — all drugs for Neoadjuvant Immunotherapy →
- Radiotherapy — all drugs for Radiotherapy →
- Lung Surgery — all drugs for Lung Surgery →
Sponsor
Peking University Cancer Hospital & Institute
Who can join
18 and older, any sex, with Lung Cancer (NSCLC) or Neoadjuvant Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prognostic value of <sup>18</sup>F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer who achieved a pathological complete response after neoadjuvant chemoimmunotherapy.
Tao Y, Guo R, Li X, Cui X, et al · · 2026 · PMID 42237141 · DOI 10.1186/s40644-026-01057-1 -
Immune checkpoint blockade in cancer: current insights and future horizons.
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, et al · · 2026 · PMID 41483376 · DOI 10.1007/s12672-025-04361-7
Verify or expand the search:
- PubMed search for NCT06926179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of neoadjuvant immunotherapy
Trials testing the same drug.
- NCT06762158 — NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC · NA · active not recruiting
- NCT05273827 — Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium · completed
Other recruiting trials for Lung Cancer (NSCLC)
Currently open trials in the same condition.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT07379476 — Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT07103395 — A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade · Phase 2 · recruiting
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
- NCT07120282 — Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC · Phase 2 · recruiting
Other Peking University Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
- NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06926179 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
- Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06926179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing